An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd ...

Let’s look specifically at dexamethasone, a common corticosteroid ... however this cohort of patients had less severe symptoms [8]. While sick COVID-19 patients benefit from dex, there is ...

New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...

Metagenomi (MGX) presented updated preclinical NHP data for its hemophilia A program in an oral presentation at the American Society of ...

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...

No patients discontinued treatment due to AEs, and no unexpected serious AEs occurred that were attributed to the anti-emetic regimen of palonosetron and dexamethasone. The most common AEs that ...

Average pain in the group treated with dexamethasone prior to the desired intervention was 8.11 ± 1.31 and it was 8 ± 1.52 in groups treated with propofol. The independent T-test results showed ...

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through ...

DelveInsight has recently released a series of epidemiology-based market reports focusing on blood disorders including Immune ...

Researchers sought to determine whether it would be beneficial to add inotuzumab to the CALGB 10403 pediatric regimen in the treatment of young adults with CD22-positive B-ALL.

After hours: December 6 at 4:01:51 PM EST Loading Chart for MG ...